Serum Irisin and Asprosin Levels as Potential Biomarkers an Type 2 Diabetes Mellitus and its Renal Complications: A Biochemical Investigation of Hormonal and Metabolic Profiles

Aqeel M. Rasool; Alaa Hussein J. Al-Qaisi

doi:10.61132/obat.v4i1.1960

Authors

Aqeel M. Rasool Directorate of Education Al-Muthanna, Al-Samawah, Al-Muthanna
Alaa Hussein J. Al-Qaisi Al-Nahrain University, Jadriya, Baghdad

DOI:

https://doi.org/10.61132/obat.v4i1.1960

Keywords:

Adipocytokine, Asprosin, Diabetic nephropathy, Insulin resistance, Irisin

Abstract

This study investigates the levels of asprosin and irisin in patients with type 2 diabetes mellitus (T2DM) and diabetic nephropathy (DN), and evaluates their relationships with insulin resistance, glycemic control, and renal function. Additionally, it explores their diagnostic performance as potential non-invasive biomarkers for the early detection of DN using ROC curve analysis. A controlled prospective study was conducted involving 130 participants, categorized into healthy controls, T2DM patients, and T2DM with DN. Serum asprosin, irisin, and insulin levels were measured using ELISA, while biochemical and renal parameters such as fasting blood glucose, HbA1c, creatinine, urea, and eGFR were assessed using standard spectrophotometric techniques. ROC analysis was employed to assess the diagnostic accuracy of asprosin and irisin. Asprosin levels were significantly elevated, while irisin levels were markedly reduced in DN patients compared to T2DM and control groups (p < 0.001). Moreover, DN patients exhibited higher levels of fasting glucose, HbA1c, HOMA-IR, creatinine, and urea, with lower eGFR, indicating substantial renal dysfunction. ROC analysis revealed that asprosin had an AUC of 0.910 (95% CI: 0.839–0.981), with 90.0% sensitivity and 88.9% specificity at a cutoff value of 11.27 ng/mL. Irisin showed an AUC of 0.886 (95% CI: 0.812–0.960), with 95.0% sensitivity and 71.1% specificity at a 158.25 ng/mL cutoff. Asprosin and irisin are strongly associated with insulin resistance and renal impairment in patients with T2DM and DN. Their high diagnostic performance supports their utility as promising non-invasive biomarkers for the early detection and monitoring of diabetic nephropathy progression.

Downloads

Download data is not yet available.

References

1. Jannah M, Hidayati P, Mulyadi F, Kartika I, Irmayanti I. The Relationship between HbA1c, GDP and Disease Duration on the Occurrence of Diabetic Neuropathy at Ibnu Sina Hospital. Formosa J Sci Technol. 2024 Aug 29;3:1893–904.

2. Aly RH, Ahmed AE, Hozayen WG, Rabea AM, Ali TM, El Askary A, et al. Patterns of Toll-Like Receptor Expressions and Inflammatory Cytokine Levels and Their Implications in the Progress of Insulin Resistance and Diabetic Nephropathy in Type 2 Diabetic Patients. Front Physiol. 2020;11:609223.

3. Yang M, Chen P, Jin H, Xie X, Gao T, Yang L, et al. Circulating levels of irisin in middle-aged first-degree relatives of type 2 diabetes mellitus - correlation with pancreatic β-cell function. Diabetol Metab Syndr. 2014;6(1):133.

4. Hou Q, Song R, Zhao X, Yang C, Feng Y. Lower circulating irisin levels in type 2 diabetes mellitus patients with chronic complications: A meta-analysis. Heliyon [Internet]. 2023;9(11):e21859.

5. Poznyak A, Grechko A V., Poggio P, Myasoedova VA, Alfieri V, Orekhov AN. The diabetes mellitus–atherosclerosis connection: The role of lipid and glucose metabolism and chronic inflammation. Int J Mol Sci. 2020;21(5):1–13.

6. Aly RH, Ahmed AE, Hozayen WG, Rabea AM, Ali TM, El Askary A, et al. Patterns of toll-like receptor expressions and inflammatory cytokine levels and their implications in the progress of insulin resistance and diabetic nephropathy in type 2 diabetic patients. Front Physiol. 2020;11(December).

7. Jha R, Lopez-Trevino S, Kankanamalage HR, Jha JC. Diabetes and Renal Complications: An Overview on Pathophysiology, Biomarkers and Therapeutic Interventions. Biomedicines. 2024;12(5):1–23.

8. Swaminathan SM, Bhojaraja MV, Attur RP, Rao IR, Rangaswamy D, Shenoy SV, et al. Study of clinical and histopathological factors predicting rapid progression in biopsy-proven type 2 diabetic kidney disease. J Nephropathol. 2024;13(4).

9. Serrano E, Shenoy P, Martinez Cantarin MP. Adipose tissue metabolic changes in chronic kidney disease. Immunometabolism (United States). 2023;5(2):E00023.

10. Majeed AA, Al-Qaisi AHJ, Ahmed WA. The Comparison of Irisin, Subfatin, and Adropin in Normal-Weight and Obese Polycystic Ovary Syndrome Patients. Iran J Med Sci. 2024 Jun;49(6):350–8.

11. Romere C, Duerrschmid C, Bournat J, Constable P, Jain M, Xia F, et al. Asprosin, a Fasting-Induced Glucogenic Protein Hormone. Vol. 165, Cell. 2016. p. 566–79.

12. Zeng X, Sun X, He W, Xie J, Xin C. Relationship of asprosin and diabetes: a meta-analysis. BMC Endocr Disord. 2025;25(1):15.

13. Yuan M, Li W, Zhu Y, Yu B, Wu J. Asprosin: A Novel Player in Metabolic Diseases. Front Endocrinol (Lausanne). 2020;11:64.

14. Luo Y, Qiao X, Xu L, Huang G. Irisin: circulating levels in serum and its relation to gonadal axis. Endocrine. 2022 Mar;75(3):663–71.

15. Paoletti I, Coccurello R. Irisin: A Multifaceted Hormone Bridging Exercise and Disease Pathophysiology. Int J Mol Sci. 2024;25(24):1–28.

16. Li X, Lindholm B. The role of irisin in kidney diseases. Clin Chim Acta. 2024 Feb;554:117756.

17. Jankowski J. Diagnosis and treatment of chronic kidney diseases and Type 2 diabetes mellitus: a paradigm shift for enhancing cardiovascular prognosis. J Intern Med. 2025 Jan 20;

18. Osikov M, Efros LA, Zhuravleva Ly, Fedosov AA. Dynamic changes of inflammatory markers in the early stages of chronic kidney disease in patients with type 1 diabetes mellitus. Bull Russ State Med Univ. 2024 Dec 23;

19. Schrank Y, Fontes R, Perozo AFDF, Araújo PB, Pinheiro MFMC, Gomes DMV, et al. Proposal for fasting insulin and HOMA-IR reference intervals based on an extensive Brazilian laboratory database. Arch Endocrinol Metab . 2024;68:1–8.

20. Zhang H, Hu W, Zhang G. Circulating asprosin levels are increased in patients with type 2 diabetes and associated with early-stage diabetic kidney disease. Vol. 52, International Urology and Nephrology. 2020. p. 1517–22.

21. Hou Q, Song R, Zhao X, Yang C, Feng Y. Lower circulating irisin levels in type 2 diabetes mellitus patients with chronic complications: A meta-analysis. Heliyon. 2023;9(11):e21859.

22. Liu Y, Qian SW, Tang Y, Tang QQ. The secretory function of adipose tissues in metabolic regulation. Life Metab. 2024;3(2).

23. Kagdi S, Lyons SA, Beaudry JL. The interplay of glucose-dependent insulinotropic polypeptide in adipose tissue. J Endocrinol. 2024;261(3).

24. Gamal S, Ibrahim S, El-deib AE raouf M, Abu- ST. Relation between Obesity , Insulin Resistance and T2DM : Review Article. 2024;3(1).

25. Shabir K, Brown JE, Afzal I, Gharanei S, Weickert MO, Barber TM, et al. Asprosin, a novel pleiotropic adipokine implicated in fasting and obesity-related cardio-metabolic disease: Comprehensive review of preclinical and clinical evidence. Cytokine Growth Factor Rev. 2021;60:120–32.

26. Mazur-Bialy AI. Asprosin-A Fasting-Induced, Glucogenic, and Orexigenic Adipokine as a New Promising Player. Will It Be a New Factor in the Treatment of Obesity, Diabetes, or Infertility? A Review of the Literature. Nutrients. 2021 Feb;13(2).

27. Romere C, Duerrschmid C, Bournat J, Petra C, Jain M, Xia F, et al. 乳鼠心肌提取 HHS Public Access. Cell. 2017;176(1):139–48.

28. Mirr M, Braszak-Cymerman A, Ludziejewska A, Kręgielska-Narożna M, Bogdański P, Bryl W, et al. Serum Asprosin Correlates with Indirect Insulin Resistance Indices. Biomedicines. 2023 May;11(6).

29. Clark M, Hoenig M. Metabolic Effects of Obesity and Its Interaction with Endocrine Diseases. Vet Clin North Am Small Anim Pract. 2016 Sep;46(5):797–815.

30. García-Fontana B, Reyes-García R, Morales-Santana S, Ávila-Rubio V, Muñoz-Garach A, Rozas-Moreno P, et al. Relationship between myostatin and irisin in type 2 diabetes mellitus: a compensatory mechanism to an unfavourable metabolic state? Endocrine. 2016;52(1):54–62.

31. Mageswari R, Sridhar MG, Nandeesha H, Parameshwaran S, Vinod K V. Irisin and Visfatin Predicts Severity of Diabetic Nephropathy. Vol. 34, Indian Journal of Clinical Biochemistry. 2019. p. 342–6.

32. Kamel SM, Ahmed NS, El Moety MAA, El Hameed NA. Fibronectin type-III domain-containing protein 5 genetic polymorphism and serum irisin-level change in relation to type-2 diabetes mellitus with diabetic nephropathy. J Egypt Soc Nephrol Transplant. 2023;23(3).

33. Rodríguez-Carmona A, Fontán MP, Alvarellos SS, Falcón TG, Bello MLP, Muniz AL, et al. Serum levels of the adipomyokine irisin in patients with chronic kidney disease. Nefrol (English Ed. 2016;36(5):496–502.

34. Gizaw M, Anandakumar P, Debela T. A Review on the Role of Irisin in Insulin Resistance and Type 2 Diabetes Mellitus. J pharmacopuncture. 2017 Dec;20(4):235–42.

35. Wang L, Song J, Wang C, Lin P, Liang K, Sun Y, et al. Circulating Levels of Betatrophin and Irisin Are Not Associated with Pancreatic β-Cell Function in Previously Diagnosed Type 2 Diabetes Mellitus Patients. J Diabetes Res. 2016;2016.

36. Chen JQ, Huang YY, Gusdon AM, Qu S. Irisin: A new molecular marker and target in metabolic disorder. Lipids Health Dis. 2015;14(1):1–6.

37. Xuan X, Lin J, Zhang Y, Zhou L, Xu L, Jia J, et al. Serum Irisin Levels and Clinical Implication in Elderly Patients With Type 2 Diabetes Mellitus. J Clin Med Res. 2020;12(9):612–7.

38. Pedersen BK, Steensberg A, Fischer C, Keller C, Keller P, Plomgaard P, et al. Searching for the exercise factor: is IL-6 a candidate? J Muscle Res Cell Motil. 2003;24(2):113–9.

39. Shelbaya S, Abu Shady MM, Nasr MS, Bekhet MM, Mageed YAA, Abbas M. Study of irisin hormone level in type 2 diabetic patients and patients with diabetic nephropathy. Curr Diabetes Rev. 2018;14(5):481–6.

40. Wang Hongyan RL. Association Between Serum Irisin and Diabetic Nephropathy in Patients with Type 2 Diabetes Mellitus: A Meta-Analysis. Horm Metab Res [Internet]. 2021;53(05):293–300.

41. Du XL, Jiang WX, Lv ZT. Lower Circulating Irisin Level in Patients with Diabetes Mellitus: A Systematic Review and Meta-Analysis. Horm Metab Res = Horm und Stoffwechselforsch = Horm Metab. 2016 Sep;48(10):644–52.